AstraZeneca Tezspire trial success
Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The positive trial results may restore some confidence in AstraZeneca's pipeline, potentially supporting its share price after a 14% decline since Wainua's failure. However, investors remain cautious, focusing on upcoming cancer trial results, limiting immediate market impact.
AstraZeneca announced on August 27, 2026 that its asthma drug Tezspire, developed with Amgen, met the main goals of a late-stage trial in patients with eosinophilic esophagitis, a chronic inflammatory disorder of the esophagus. The study showed significant reduction in esophageal inflammation and eased difficulty in swallowing compared to placebo at 52 weeks. This success offers a boost after a series of pipeline setbacks, including failures of Wainua, Ultomiris, and camizestrant, and the halt of volrustomig trial. Tezspire is already approved for severe asthma in the US and EU, competing with Sanofi and Regeneron's Dupixent. The drug generated $1.13 billion in sales for AstraZeneca and $1.48 billion for Amgen in 2025. Investors remain focused on upcoming results from two cancer trials seen as critical to AstraZeneca's pipeline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard